Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track

Zura Bio Ltd

2025-Q1 EPS reported -$0.19

Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).
Cash and equivalents $170.6M; runway expected to fund operations through 2027.
Phase 2 TibuSURE trial for systemic sclerosis continues; HS Phase 2 expected Q2 2025.
Appointed Kate Dingwall as SVP of Development Operations to support clinical execution.
G&A expenses $8.8M, increased $4.0M YoY due to compensation and professional fees.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-045865
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2025-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:50.192494+00:00
generated_at: 2026-05-22T05:32:37.101356+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-045865
json_url: https://secwatch.observer/filing/0001104659-25-045865.json
markdown_url: https://secwatch.observer/filing/0001104659-25-045865.md
text_url: https://secwatch.observer/filing/0001104659-25-045865.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/0001104659-25-045865-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/tm2514121d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-045865

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.